TCDA on NASDAQ
Tricida
American pharmaceutical company based in Menlo Park, incorporated in Delaware.1
Price unavailable
Last updated Oct 18, 2026.
Overview
Jan 1, 2013Founded1
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $21.8M4 | $35.9M5 | $85.6M6 | $133.0M6 | $148.4M7 | $115.4M7 | ||
| Selling, general and admin | $5.4M4 | $11.2M5 | $18.0M6 | $45.8M6 | $103.0M7 | $37.6M7 | ||
| Operating income | -$27.2M4 | -$47.1M5 | -$103.6M6 | -$178.8M6 | -$251.4M7 | -$153.0M7 | ||
| Interest | $04 | $05 | $3.1M6 | $5.7M6 | $18.4M7 | $17.6M7 | ||
| Income tax | $05 | $06 | -$92.0K6 | $07 | $07 | |||
| Net income | -$28.7M4 | -$41.3M5 | -$102.8M6 | -$176.8M6 | -$264.8M7 | -$176.6M7 | ||
| Earnings per share | -$5.297 | -$3.447 | ||||||
| Earnings per share (diluted) | -$5.297 | -$3.447 |
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Cash | $6.1M4 | $5.7M5 | $9.8M4 | $37.2M5 | $18.6M6 | $137.9M7 | $21.1M7 | |
| Current assets | $69.4M4 | $244.3M5 | $312.7M6 | $314.0M7 | $145.5M7 | |||
| Total assets | $70.6M4 | $247.8M5 | $371.8M6 | $351.7M7 | $168.5M7 | |||
| Current liabilities | $11.2M4 | $14.8M5 | $39.8M6 | $34.3M7 | $29.5M7 | |||
| Long-term debt | $04 | $38.1M5 | $58.4M6 | $76.6M7 | $07 | |||
| Total liabilities | $11.5M4 | $53.3M5 | $107.9M6 | $242.8M7 | $168.3M7 | |||
| Shareholders’ equity | -$19.3M4 | -$47.6M5 | -$88.0M6 | $194.5M6 | $263.9M7 | $108.9M7 | $218.0K7 | |
| Shares outstanding | 2.3M shares4 | 42.1M shares5 | 49.8M shares6 | 50.2M shares7 | 55.4M shares7 | 55.4M shares7 |
Leadership
Who has led Tricida, and when. Pick a name to see everywhere that person has worked.
- Chief executive officerGerrit Klaerner Jun 27, 2018 to Mar 2, 202210
- PresidentGerrit Klaerner Jun 27, 2018 to Mar 2, 202210
Board members and other officers (17)
- SVP, Finance & CAOMarc Cobo Jul 1, 2020 to Sep 14, 202011
- VP, Finance and CAOAnnie Yoshiyama Dec 8, 2020 to Aug 9, 202212
- Sr. VP, Chief Comm. OfficerSusannah Cantrell Jan 30, 2019 to Sep 14, 202013
- Chief Comm Officer and Sr VPBeek Jeroen B. Van Jun 27, 2018 to Jul 2, 201814
- Chief Dev. Officer and Sr. VPClaire Lockey Jun 27, 2018 to Nov 5, 201915
- Chief Scientific Offr & Sr VPJerry M. Buysse Jun 27, 2018 to Jun 27, 201816
- VP Fin & Chief Acct OfficerSteffen Pietzke Jun 27, 2018 to Feb 26, 202017
- Chief Tech Officer & Sr. VPWilhelm Stahl Jun 27, 2018 to Jan 4, 202218
- Sr VP, Clinical DevelopmentDawn Parsell Otto Aug 8, 2018 to Mar 2, 202219
- Board memberDavid P. Bonita Jun 27, 2018 to Nov 25, 202220
- Board memberGerrit Klaerner Jun 27, 2018 to Mar 2, 202210
- Board memberKathryn E. Falberg Jun 27, 2018 to Jun 16, 202221
- Board memberKlaus R. Veitinger Dr. Jun 27, 2018 to Jun 16, 202222
- Board memberRobert Alpern Jun 27, 2018 to Nov 25, 202223
- Board memberSandra I. Coufal Jun 27, 2018 to Jun 16, 202224
- General counselRobert McKague Mar 11, 2020 to Mar 2, 202225
- General counselEdward J. Hejlek Jun 27, 2018 to Mar 4, 202026
Timeline
Filings
130 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 32 major events, 62 insider forms, 17 large holders, 14 other. The latest 20:
- Jun 16, 2023EFFECT EDGAR
- Jun 13, 202315-12G EDGAR
- Jun 13, 2023S-8 POS EDGAR
- Jun 13, 2023POSASR EDGAR
- Jun 13, 2023POS AM EDGAR
- Jun 13, 20238-K EDGAR
- May 25, 20238-K EDGAR
- Apr 26, 20238-K EDGAR
- Mar 24, 20238-K EDGAR
- Mar 21, 20238-K EDGAR
- Mar 15, 20238-K EDGAR
- Feb 24, 20238-K EDGAR
- Feb 23, 20238-K EDGAR
- Feb 17, 20238-K EDGAR
- Feb 14, 2023SC 13G/A EDGAR
- Feb 14, 2023SC 13G/A EDGAR
- Feb 14, 2023SC 13G/A EDGAR
- Feb 14, 2023SC 13G/A SCHEDULE 13G/A, AMENDMENT #2 EDGAR
- Jan 27, 20238-K EDGAR
- Jan 17, 20238-K EDGAR
The 130 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 17 such filings since October 2021, the latest 10:
- Feb 14, 2023SC 13G/A
- Feb 14, 2023SC 13G/A
- Feb 14, 2023SC 13G/A
- Feb 14, 2023SC 13G/A
- Dec 16, 2022SC 13D/A
- Nov 25, 2022SC 13D/A
- Oct 28, 2022SC 13G/A
- Oct 28, 2022SC 13G
- Oct 19, 2022SC 13D/A
- Sep 29, 2022SC 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Links
- Websitewww.tricida.com1
- X (Twitter)x.com/tricida1
- WikidataQ99744172
- SEC EDGARCIK 1595585
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataTricida on Wikidata
- 2SEC EDGARTricida filings on SEC EDGAR
- 3SEC EDGARTricida filings on SEC EDGAR
- 4SEC EDGARTricida 10-K for fiscal 2016
- 5SEC EDGARTricida 10-K for fiscal 2017
- 6SEC EDGARTricida 10-K for fiscal 2018
- 7SEC EDGARTricida 10-K for fiscal 2020
- 8SEC EDGARTricida 10-Q for fiscal 2022
- 9SEC EDGARTricida 10-Q for fiscal 2022
- 10
- 11SEC EDGARMarc Cobo, SVP, Finance & CAO
- 12SEC EDGARAnnie Yoshiyama, VP, Finance and CAO
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARDavid P. Bonita, Board member
- 21SEC EDGARKathryn E. Falberg, Board member
- 22SEC EDGARKlaus R. Veitinger Dr., Board member
- 23SEC EDGARRobert Alpern, Board member
- 24SEC EDGARSandra I. Coufal, Board member
- 25SEC EDGARRobert McKague, General counsel
- 26SEC EDGAREdward J. Hejlek, General counsel